SCT

Across TCGA pan-cancer cohorts, SCT mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SCT data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SCT mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SCT expression acts as an unfavorable survival marker.

GBM, PDAC, and CCRCC are the cancer types where SCT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.279	0.583	.030	4	view →
PDAC	DFS	Median	All	0.237	0.797	.037	4	view →
CCRCC	DFS	Quartile	All	0.701	0.933	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SCT–GBM (OS)

Open the GBM breakdown →